Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2024

Pfizer Oncology - Breaking new ground: PARPi + ARPi combination therapy in mCRPC

Q&A

Date

13 Sep 2024

Session

Pfizer Oncology - Breaking new ground: PARPi + ARPi combination therapy in mCRPC

Topics

Clinical Research;  Targeted Therapy

Tumour Site

Prostate Cancer

Presenters

Neal Shore, Axel Merseburger, Eleni Efstathiou

Authors

N.D. Shore1, A.S. Merseburger2, E. Efstathiou3

Author affiliations

  • 1 Uro-oncology Department, Atlantic Urology Clinics, LLC, 29572 - Myrtle Beach/US
  • 2 Urologie, UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, 23538 - Lübeck/DE
  • 3 Gu Medical Oncology, Houston Methodist, 77025 - houston/US

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and Introductions

Presenter: Neal Shore

Session: Pfizer Oncology - Breaking new ground: PARPi + ARPi combination therapy in mCRPC

Resources:

Webcast

Conclusion

Presenter: Neal Shore

Session: Pfizer Oncology - Breaking new ground: PARPi + ARPi combination therapy in mCRPC

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.